Roger Thompson


Roger outside Chacaltaya laboratory, Bolivia; 2001
Roger Thompson is a co-founder and current chairman of Apex and was the leader of the Apex 2 expedition and deputy leader of the first Apex expedition. He is now an MRC Clinical Research Fellow and Specialist Registrar in Respiratory Medicine at the University of Sheffield.

Recent publications:

1. Network analysis reveals distinct clinical syndromes underlying acute mountain sickness.

Hall DP, Maccormick IJ, Phythian-Adams AT, Rzechorzek NM, Hope-Jones D, Cosens S, Jackson S, Bates MG, Collier DJ, Hume DA, Freeman T, Thompson AA, Baillie JK.
PLoS One. 2014 Jan 22;9(1):e81229. PMID: 24465370

2. Hypoxia-inducible factor 2alpha regulates key neutrophil functions in humans, mice, and zebrafish.

Thompson AA, Elks PM, Marriott HM, Eamsamarng S, Higgins KR, Lewis A, Williams L, Parmar S, Shaw G, McGrath EE, Formenti F, Van Eeden FJ, Kinnula VL, Pugh CW, Sabroe I, Dockrell DH, ... ...Johnson RS, Renshaw SA, Whyte MK, Walmsley SR.
Blood. 2014 Jan 16;123(3):366-76. PMID: 24196071

3. Hypoxia, the HIF pathway and neutrophilic inflammatory responses.

Thompson AA, Binham J, Plant T, Whyte MK, Walmsley SR.
Biol Chem. 2013 Apr;394(4):471-7. PMID: 23324383

4. Retinal vessel tortuosity in response to hypobaric hypoxia.

MacCormick IJ, Somner J, Morris DS, MacGillivray TJ, Bourne RR, Huang SS, MacCormick A, Aspinall PA, Baillie JK, Thompson AA, Dhillon B.
High Alt Med Biol. 2012 Dec;13(4):263-8. PMID: 23270443

5. A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia.

Marriott HM, Daigneault M, Thompson AA, Walmsley SR, Gill SK, Witcher DR, Wroblewski VJ, Hellewell PG, Whyte MK, Dockrell DH.
Thorax. 2012 Nov;67(11):985-92. PMID: 22735687

6. Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis.

McGrath EE, Lawrie A, Marriott HM, Mercer P, Cross SS, Arnold N, Singleton V, Thompson AA, Walmsley SR, Renshaw SA, Sabroe I, Chambers RC, Dockrell DH, Whyte MK.
Thorax. 2012 Sep;67(9):796-803. PMID: 22496351

7. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial.

Bates MG, Thompson AA, Baillie JK, Sutherland AI, Irving JB, Hirani N, Webb DJ.
High Alt Med Biol. 2011 Fall;12(3):207-14. PMID: 21962063

8. Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice.

Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P, Whyte MK.
J Clin Invest. 2011 Mar;121(3):1053-63. PMID: 21317538

9. Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophils.

McGovern NN, Cowburn AS, Porter L, Walmsley SR, Summers C, Thompson AA, Anwar S, Willcocks LC, Whyte MK, Condliffe AM, Chilvers ER.
J Immunol. 2011 Jan 1;186(1):453-63. PMID: 21135168

10. Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro.

Jackson SJ, Varley J, Sellers C, Josephs K, Codrington L, Duke G, Njelekela MA, Drummond G, Sutherland AI, Thompson AA, Baillie JK.
High Alt Med Biol. 2010 Fall;11(3):217-22. PMID: 20919888

11. A complication of peroral bronchoscopy.

Thompson AA, Raistrick CS, Pirzada OM, Anderson PB.
Eur Respir J. 2010 Jan;35(1):221-2. PMID: 20044464

12. The citric acid cough threshold and the ventilatory response to carbon dioxide on ascent to high altitude.

Thompson AA, Baillie JK, Bates MG, Schnopp MF, Simpson A, Partridge RW, Drummond GB, Mason NP.
Respir Med. 2009 Aug;103(8):1182-8. PMID: 19303278

13. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial.

Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, Macnee W, Maxwell SR, Webb DJ.
QJM. 2009 May;102(5):341-8. PMID: 19273551

14. NT-proBNP does not rise on acute ascent to high altitude.

Toshner MR, Thompson AA, Irving JB, Baillie JK, Morton JJ, Peacock AJ.
High Alt Med Biol. 2008 Winter;9(4):307-10. PMID: 19115915

15. Manual assessment of the initial fall in blood pressure after orthostatic challenge at high altitude.

Mytton OT, Simpson A, Thompson AA, Oram RA, Darowski A, Yu LM, Collier DJ, Pollard AJ.
Wilderness Environ Med. 2008 Winter;19(4):225-32. PMID: 19099326

16. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude.

Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp MF, Simpson A, Gulliver-Sloan F, Maxwell SR, Webb DJ.
Chest. 2007 May;131(5):1473-8. PMID: 17494796

17. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.

Bates MG, Thompson AA, Baillie JK.
Curr Opin Investig Drugs. 2007 Mar;8(3):226-31. PMID: 17408118

18. Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude.

Smith EM, Baillie JK, Thompson AA, Irving JB, Porteous D, Webb DJ.
High Alt Med Biol. 2006 Fall;7(3):221-7. PMID: 16978134

19. Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness.

Dorward DA, Thompson AA, Baillie JK, MacDougall M, Hirani N.
Respir Med. 2007 Mar;101(3):587-94. PMID: 16890420

20. Catastrophe for a campanologist.

Thompson AA, McRoberts RJ, McKie S, Oglesby AJ.
Eur J Emerg Med. 2006 Jun;13(3):184-6. PMID: 16679888

21. Pericardial effusions in healthy lowlanders after acute ascent to high altitude.

Thompson AA, Baillie JK, Toshner M, Maxwell SR, Webb DJ, Irving JB.
Heart. 2006 Apr;92(4):539-40. PMID: 16537774